These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. [Circumventing multidrug resistance in human cancer by anti-ribozyme]. Funato T Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162 [TBL] [Abstract][Full Text] [Related]
64. Antisense DNA and RNA strategies: new approaches to therapy. Gibson I J R Coll Physicians Lond; 1994; 28(6):507-11. PubMed ID: 7884705 [TBL] [Abstract][Full Text] [Related]
65. HIV and Ribozymes. Scarborough RJ; Gatignol A Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617 [TBL] [Abstract][Full Text] [Related]
66. Repression of hepatitis B virus X gene expression by hammerhead ribozymes. Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856 [TBL] [Abstract][Full Text] [Related]
67. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650 [TBL] [Abstract][Full Text] [Related]
68. Hepatitis C IRES: translating translation into a therapeutic target. Jubin R Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352 [TBL] [Abstract][Full Text] [Related]
69. RNA as a target for developing antivirals. McKnight KL; Heinz BA Antivir Chem Chemother; 2003 Mar; 14(2):61-73. PubMed ID: 12856917 [TBL] [Abstract][Full Text] [Related]
73. Biologic activity of oligonucleotides with polarity and anomeric center reversal. Tan TM; Kalisch BW; van de Sande JH; Ting RC; Tan YH Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):95-101. PubMed ID: 9593047 [TBL] [Abstract][Full Text] [Related]
74. The application of ribozymes to HIV infection. Rossi JJ Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796 [TBL] [Abstract][Full Text] [Related]
75. Exploiting genetic alterations to design novel therapies for cancer. Cripe TP; Mackall CL Hematol Oncol Clin North Am; 2001 Aug; 15(4):657-75, viii. PubMed ID: 11676278 [TBL] [Abstract][Full Text] [Related]
76. Papillomaviruses as targets for cancer gene therapy. Shillitoe EJ; Kamath P; Chen Z Cancer Gene Ther; 1994 Sep; 1(3):193-204. PubMed ID: 7621251 [TBL] [Abstract][Full Text] [Related]
77. Antisense strategies in degenerative joint diseases: sense or nonsense? Huber LC; Distler O; Gay RE; Gay S Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269 [TBL] [Abstract][Full Text] [Related]
78. Gene therapy in hematology. Benz EJ; Bank A Rev Invest Clin; 1994 Apr; Suppl():143-6. PubMed ID: 7886298 [No Abstract] [Full Text] [Related]
79. [Development of antisense nucleotides for therapy]. Wang J; Wang L; Wang Y Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848 [TBL] [Abstract][Full Text] [Related]
80. Antisense applications for biological control. Pan WH; Clawson GA J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]